Depomed granted drug delivery combination patent

Published: 4-Feb-2004

Depomed has been issued with a US Patent 6,682,759, covering methods for manufacturing a tablet that delivers two drugs with different characteristics in a single dose.


Depomed has been issued with a US Patent 6,682,759, covering methods for manufacturing a tablet that delivers two drugs with different characteristics in a single dose.

Depomed is currently applying this technology to a tablet that combines Metformin GR, the company's once daily, controlled-release diabetes drug, with a coating of sulfonylurea, a drug frequently prescribed in combination with metformin to manage Type II diabetes. Depomed's Metformin GR/sulfonylurea combination product is in preclinical development.

'The availability of many drugs to treat diseases has given physicians the option to create a customised combination of treatments for each patient,' said Dr John Fara, chairman, president and ceo of Depomed. 'We believe that technologies such as Depomed's combination gastric retention (GR) tablet, which can combine multiple drugs in a single dose, will provide patients with a more convenient alternative to taking several tablets at a time. If tested in trials and approved, our once daily Metformin GR/sulfonylurea combination product can address an important, unmet need.'

You may also like